TOKYO (Reuters): Japanese pharmaceuticals company KM Biologics Co has already seen overseas interest in its monkeypox vaccine which was recently approved by domestic regulators.
KM Biologics, a unit of candy maker Meiji Holdings Co, has had "several inquiries from overseas" a company official told Reuters on Wednesday (Aug 3), declining to comment on any export plan for the shot.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
